MaxCyte, Inc. Operating Expenses
MaxCyte, Inc. (MXCT) reported Operating Expenses of $15.83 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- MaxCyte, Inc. operating expenses for the quarter ending 2026-06-30 was $15.83M, a 25.39% decline year-over-year.
- MaxCyte, Inc. operating expenses for the quarter ending 2026-03-31 was $14.27M, a 32.66% decline year-over-year.
- MaxCyte, Inc. operating expenses for the quarter ending 2025-12-31 was $16.92M, a 12.41% decline year-over-year.
- MaxCyte, Inc. operating expenses for the quarter ending 2025-09-30 was $19.38M, a 4.47% decline year-over-year.
- MaxCyte, Inc. operating expenses for fiscal 2025 was $78.70M, a 4.86% decline from fiscal 2024.
- MaxCyte, Inc. operating expenses for fiscal 2024 was $82.72M, a 2.50% decline from fiscal 2023.
- MaxCyte, Inc. operating expenses for fiscal 2023 was $84.84M, a 27.54% increase from fiscal 2022.
- MaxCyte, Inc. operating expenses for fiscal 2022 was $66.52M, a 37.35% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $15.83M 10-Q · filed 2026-08-13 | $30.09M 10-Q · filed 2026-08-13 | $47.01M derived: sum of 3 quarters · filed 2026-08-13 | $66.39M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $14.27M 10-Q · filed 2026-05-13 | $31.18M derived: sum of 2 quarters · filed 2026-05-13 | $50.56M derived: sum of 3 quarters · filed 2026-05-13 | $71.78M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $16.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $36.30M derived: sum of 2 quarters · filed 2026-03-25 | $57.51M derived: sum of 3 quarters · filed 2026-08-13 | $78.70M 10-K · filed 2026-03-25 | |||
| 2025-09-30 | $19.38M 10-Q · filed 2025-11-13 | $40.60M derived: sum of 2 quarters · filed 2026-08-13 | $61.78M 10-Q · filed 2025-11-13 | $81.10M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $21.21M 10-Q · filed 2026-08-13 | $42.40M 10-Q · filed 2026-08-13 | $61.72M derived: sum of 3 quarters · filed 2026-08-13 | $82.00M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $21.19M 10-Q · filed 2026-05-13 | $40.50M derived: sum of 2 quarters · filed 2026-05-13 | $60.79M derived: sum of 3 quarters · filed 2026-05-13 | $81.70M derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | $19.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $39.60M derived: sum of 2 quarters · filed 2026-03-25 | $60.51M derived: sum of 3 quarters · filed 2026-03-25 | $82.72M 10-K · filed 2026-03-25 | |||
| 2024-09-30 | $20.29M 10-Q · filed 2025-11-13 | $41.20M derived: sum of 2 quarters · filed 2025-11-13 | $63.41M 10-Q · filed 2025-11-13 | $85.60M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $20.91M 10-Q · filed 2025-08-06 | $43.12M 10-Q · filed 2025-08-06 | $65.31M derived: sum of 3 quarters · filed 2025-08-06 | $86.47M derived: sum of 4 quarters · filed 2025-08-06 | |||
| 2024-03-31 | $22.21M 10-Q · filed 2025-05-08 | $44.40M derived: sum of 2 quarters · filed 2025-05-08 | $65.56M derived: sum of 3 quarters · filed 2025-05-08 | $86.31M derived: sum of 4 quarters · filed 2025-05-08 | |||
| 2023-12-31 | $22.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $43.35M derived: sum of 2 quarters · filed 2025-03-11 | $64.09M derived: sum of 3 quarters · filed 2025-03-11 | $84.84M 10-K · filed 2025-03-11 | |||
| 2023-09-30 | $21.16M 10-Q · filed 2024-11-06 | $21.16M 10-Q · filed 2023-11-08 | $41.90M derived: sum of 2 quarters · filed 2024-11-06 | $62.66M 10-Q · filed 2024-11-06 | $62.66M 10-Q · filed 2023-11-08 | $80.28M derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | $20.74M 10-Q · filed 2024-08-06 | $20.74M 10-Q · filed 2023-08-09 | $41.49M 10-Q · filed 2024-08-06 | $59.12M derived: sum of 3 quarters · filed 2024-08-06 | $76.11M derived: sum of 4 quarters · filed 2024-08-06 | ||
| 2023-03-31 | $20.75M 10-Q · filed 2024-05-07 | $20.75M 10-Q · filed 2023-05-10 | $38.38M derived: sum of 2 quarters · filed 2024-05-07 | $55.37M derived: sum of 3 quarters · filed 2024-05-07 | $72.59M derived: sum of 4 quarters · filed 2024-05-07 | ||
| 2022-12-31 | $17.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $34.61M derived: sum of 2 quarters · filed 2024-03-12 | $51.84M derived: sum of 3 quarters · filed 2024-03-12 | $66.52M 10-K · filed 2024-03-12 | $66.52M 10-K · filed 2023-03-15 | ||
| 2022-09-30 | $16.99M 10-Q · filed 2023-11-08 | $34.21M derived: sum of 2 quarters · filed 2023-11-08 | $48.90M 10-Q · filed 2023-11-08 | $62.78M derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $17.23M 10-Q · filed 2023-08-09 | $31.91M 10-Q · filed 2023-08-09 | $45.79M derived: sum of 3 quarters · filed 2023-08-09 | $57.43M derived: sum of 4 quarters · filed 2023-08-09 | |||
| 2022-03-31 | $14.68M 10-Q · filed 2023-05-10 | $28.57M derived: sum of 2 quarters · filed 2023-05-10 | $40.20M derived: sum of 3 quarters · filed 2023-05-10 | $50.94M derived: sum of 4 quarters · filed 2023-05-10 | |||
| 2021-12-31 | $13.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $25.52M derived: sum of 2 quarters · filed 2023-03-15 | $36.26M derived: sum of 3 quarters · filed 2023-03-15 | $48.44M 10-K · filed 2023-03-15 | |||
| 2021-09-30 | $11.64M 10-Q · filed 2022-11-09 | $22.38M derived: sum of 2 quarters · filed 2022-11-09 | $34.55M 10-Q · filed 2022-11-09 | $44.54M derived: sum of 4 quarters · filed 2022-11-09 | |||
| 2021-06-30 | $10.74M 10-Q · filed 2022-08-10 | $22.92M 10-Q · filed 2022-08-10 | $32.90M derived: sum of 3 quarters · filed 2022-08-10 | $41.77M derived: sum of 4 quarters · filed 2022-08-10 | |||
| 2021-03-31 | $12.17M 10-Q · filed 2022-05-09 | $22.16M derived: sum of 2 quarters · filed 2022-05-09 | $31.03M derived: sum of 3 quarters · filed 2022-05-09 | $38.56M derived: sum of 4 quarters · filed 2022-05-09 | |||
| 2020-12-31 | $9.99M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $18.86M derived: sum of 2 quarters · filed 2022-03-22 | $26.39M derived: sum of 3 quarters · filed 2022-03-22 | $34.46M 10-K · filed 2022-03-22 | |||
| 2020-09-30 | $8.87M 10-Q · filed 2021-11-10 | $16.40M derived: sum of 2 quarters · filed 2021-11-10 | $24.47M 10-Q · filed 2021-11-10 | ||||
| 2020-06-30 | $7.53M 10-Q · filed 2021-09-13 | $15.60M 10-Q · filed 2021-09-13 | |||||
| 2019-12-31 | $31.54M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |